|
||||||||||||||||||||||
|
|
Antifibrosing Activity of POTABA in Agnogenic and Post-Polycythemic Myeloid Metaplasia
Basic Trial Information
Objectives I. Determine by bone marrow section examination, whether POTABA has any antifibrosing action in patients with agnogenic myeloid metaplasia (AMM) and post-polycythemic myeloid metaplasia (PPMM). Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Asymptomatic patients with AMM and PPMM with increasing spleen size (increasing splenomegaly for PPMM), absence of elevated red cell volume, development of leukoerythroblastic blood reaction plus appearance of fibrosis in AMM, tear drop poikilocytes and increased both marrow reticulin and/or fibrosis in PPMM. AMM patients must not have had prior chemotherapy. Expected Enrollment Protocol closed 11/79. Outline Nonrandomized study. Single-agent Vitamin Therapy. Potassium P-aminobenzoate, POTABA, no NSC number. Trial Lead Organizations Polycythemia Vera Study Group
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |